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Abstract
Background: Allopathic practitioners in India are outnumbered by practitioners of traditional
Indian medicine and homeopathy (TIMH), which is used by up to two-thirds of its population to
help meet primary health care needs, particularly in rural areas. India has an estimated 2.5 million
HIV infected persons. However, little is known about TIMH use, safety or efficacy in HIV/AIDS
management in India, which has one of the largest indigenous medical systems in the world. The
purpose of this review was to assess the quality of peer-reviewed, published literature on TIMH
for HIV/AIDS care and treatment.
Results: Of 206 original articles reviewed, 21 laboratory studies, 17 clinical studies, and 6 previous
reviews of the literature were identified that covered at least one system of TIMH, which includes
Ayurveda, Unani medicine, Siddha medicine, homeopathy, yoga and naturopathy. Most studies
examined either Ayurvedic or homeopathic treatments. Only 4 of these studies were randomized
controlled trials, and only 10 were published in MEDLINE-indexed journals. Overall, the studies
reported positive effects and even "cure" and reversal of HIV infection, but frequent
methodological flaws call into question their internal and external validity. Common reasons for
poor quality included small sample sizes, high drop-out rates, design flaws such as selection of
inappropriate or weak outcome measures, flaws in statistical analysis, and reporting flaws such as
lack of details on products and their standardization, poor or no description of randomization, and
incomplete reporting of study results.
Conclusion: This review exposes a broad gap between the widespread use of TIMH therapies for
HIV/AIDS, and the dearth of high-quality data supporting their effectiveness and safety. In light of
the suboptimal effectiveness of vaccines, barrier methods and behavior change strategies for
prevention of HIV infection and the cost and side effects of antiretroviral therapy (ART) for its
treatment, it is both important and urgent to develop and implement a rigorous research agenda
to investigate the potential risks and benefits of TIMH and to identify its role in the management of
HIV/AIDS and associated illnesses in India.
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The Indian health system has perhaps the world's largest
community-based indigenous system of medicine, and it
includes Ayurveda, Unani medicine, Siddha medicine,
yoga and naturopathy. [1] These forms of traditional
Indian medicine along with homeopathy (hereafter
abbreviated as TIMH) are commonly used. Reasons for
TIMH use include a strong belief in TIMH efficacy as a
"natural" and "holistic" option, and the fact that allo-
pathic care is often costly, inaccessible and culturally dis-
sonant. While the exact number of non-allopathic
providers is not known as many are unregistered, India's
Ministry of Health and Family Welfare has reported that
there are over 700,000 registered practitioners of TIMH.
[2] Over 65% of the population in rural areas of India are
using TIMH and medicinal plants to help meet their pri-
mary health care needs.[3] TIMH is used to treat a wide
variety of conditions, including cancer, diabetes and HIV/
AIDS. [4-7]
Overview of Systems of Traditional Indian Medicine
India has a long history of traditional medicine that is
well established and integrated within the overall medical
structure of the country. [8,9] In fact, there are more TIMH
practitioners (over 700,000) [2] than allopathic medical
doctors (approximately 633,000) in India, with Ayurvedic
practitioners accounting for the largest number of TIMH
providers. [10] Although TIMH use is prevalent in India,
TIMH and non-TIMH practitioners still clash over issues
involving these two domains of medicine. [11] TIMH
practitioners are still labeled by some allopathic physi-
cians as "quacks" who exploit Indian society by charging
for TIMH practices that result in little benefit. [12] On the
other hand, TIMH practitioners have not embraced the
idea of testing their timeless remedies in clinical trials in
order to meet the requirements of Western medicine. [11]
This underscores the ongoing conflicts between TIMH and
allopathic medicine in a country where TIMH is prevalent
and supported by the India government.
To address some of these issues, the Indian government
established the Department of Indian Systems of Medi-
cine and Homeopathy in 1995 and later renamed it the
Department of Ayurveda, Yoga-Naturopathy, Unani, Sid-
dha and Homoeopathy (AYUSH), which is part of the
Ministry of Health and Family Welfare. The mission of
AYUSH includes: a) an initiative for integrating AYUSH
with modern, allopathic medicine; b) attention to stand-
ardization of compounds and quality control; c) assessing
and standardizing TIMH education in institutions around
India that teach TIMH; d) improving the availability of
raw material that will be used in the manufacturing of
TIMH compounds; and e) prioritizing research on TIMH.
The Indian Government has also established a Central
Council for Research in each of these core areas, as well as
separate Directorates of AYUSH in 18 Indian States. [13]
Not all TIMH is perceived equally in India. For example,
yoga and healthy diet – which are often incorporated into
the Ayurveda, yoga and naturopathy traditions – are con-
sidered beneficial by both TIMH and allopathic providers.
However, many of the Ayurvedic herbal preparations and
homeopathic treatments for conditions such as tuberculo-
sis and HIV are discouraged by allopathic organizations
such as the Indian Medical Association, or in allopathic
medical schools, since data are lacking to support the use
of such treatments. [10] Use of TIMH is documented in
both urban and rural settings of India; however, the type
of TIMH and the prevalence of use appear to vary by
region and by rural versus urban milieu in India. [10]
Ayurveda
Ayurveda, which means "Science of Life," is a holistic
medical system that emphasizes prevention and mainte-
nance of health through creating balance of body, mind
and spirit; self-awareness and self-care; and building har-
mony in relationships with others and the universe.
Developed around 5,000 BC, many practices were passed
on by word of mouth before the advent of written texts.
[14] The Caraka Samhita and Sushruta Samhita, which are
the primary texts on Ayurvedic medicine, describe eight
branches of Ayurvedic medicine: internal medicine, sur-
gery, treatment of head and neck disease, toxicology, psy-
chiatry, sexual vitality, rejuvenation and care of the
elderly, and gynecology, obstetrics and pediatrics. [15]
Ayurvedic theory is based on three doshas (constitutional
types), and diagnosis and treatment focus more on the
individual's constitution (prakriti) than on the disease. Ill-
ness and other disorders are treated with combinations of
herbs, oils, foods, yoga and lifestyle changes tailored to
each person's constitution and designed to reduce symp-
toms, eliminate impurities, increase resistance to disease,
and promote well-being. Ayurveda is the most frequently
used system of TIMH. India has over 400,000 registered
practitioners of Ayurveda, accounting for approximately
62% of its non-allopathic providers. In addition, there are
over 2,000 Ayurvedic hospitals with nearly 44,000 beds,
and over 200 Ayurvedic teaching institutions. [10]
Siddha medicine
The Siddha system of medicine has been practiced for over
5,000 years throughout southern India [6], and its devel-
opment is attributed to 18 Siddhars, holy or "perfected"
beings believed to have had superhuman powers. Tradi-
tional Siddha medicine is similar to Ayurveda in its iden-
tification of three doshas, and it focuses on prolongation of
life through rejuvenating treatments and intense yoga
practices, such as highly regulated breathing. [16] Mineral
or metallic drugs are administered in very small quanti-Page 2 of 9
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milk, betel leaf juice and hot water), which are believed to
modify the potency, toxicity and efficacy of the drugs. [17]
Astrology and incantation are also an integral part of Sid-
dha therapy. Use of Siddha medicine is most prevalent in
Tamil Nadu, the southernmost state in India. In this state
alone, there are over 100 Siddha hospitals, nearly 300 dis-
pensaries, and over 11,000 practitioners. [13]
Unani medicine
The Unani system of medicine originated in Greece, was
enriched by Arabic experts, and arrived in India during the
medieval period. Unani theory is based on the tenet that
balance among humors (blood, phlegm, yellow bile and
black bile) is required for maintenance of health. Disease
prevention and health promotion are achieved through
emphasis on the "6 Essentials": pure air, food and water,
physical movements and rest, psychic movement and rest,
sleep and wakefulness, and retention of useful materials
and evacuation of waste materials from the body. Unani
treatments include medicines of herbal, animal, marine
and mineral origin, as well as pharmacotherapy, diet ther-
apy, and surgery. [13] There are over 42,000 registered
Unani hakims practicing in India, and there are more than
250 Unani hospitals with over 5,000 beds. [10]
Homeopathy
The system of homeopathy came to India during the life-
time of its founder Dr. Samuel Hahnemann, a German
physician who arrived around 1810 and treated patients,
including Maharaja Ranjit Singh of Punjab. [13] Home-
opathy aims to stimulate the body's natural defense
mechanisms in order to prevent or treat illness. Treatment
involves administration of very dilute doses of substances
called "remedies" that would produce similar symptoms
of illness in healthy people if they were given in larger
doses. Treatment is individualized, and practitioners
select remedies according to symptoms, lifestyle, and
emotional and mental states. Based on Indian govern-
ment data, homeopathic practitioners account for 29% of
registered TIMH providers. [10] There are over 200 home-
opathic teaching institutions and postgraduate depart-
ments in India.
Yoga
Developed in India over 5,000 years ago as a spiritual dis-
cipline, yoga is also used preventively and therapeutically.
[18] Yoga practice is traditionally composed of physical
postures, breathing exercises, meditation and relaxation.
Variations of yoga practice have spread extensively
throughout the West, where it is used primarily outside of
medical settings. This interest has generated a number of
Western scientific studies that have reported a variety of
physiological and psychological benefits. [18,19] The
Indian government does not collect data on the number
of registered practitioners of therapeutic yoga, and it
groups together research on yoga with naturopathy in its
Central Council for Research on Yoga and Naturopathy.
[13]
Naturopathy
The emphasis in naturopathy is on the patient as an inte-
grated whole, and on cultivating wellness, prevention and
self-care. The practice of naturopathy in India is divided
into two approaches: one that is based in ancient Indian
methods, and another that adopts primarily western
methods such as physiotherapy. [13] The Western model
of naturopathic medicine attempts to find the underlying
cause of the patient's condition rather than focusing solely
on symptomatic treatment, and its six fundamental prin-
ciples are "the healing power of nature, trust in the body's
inherent wisdom to heal itself, identify and treat the
causes, first do no harm, doctor as teacher, and treat the
whole person." [20] There are approximately 500 regis-
tered naturopathic practitioners in India, and just over a
dozen hospitals with approximately 1,000 beds. [10]
HIV/AIDS in India
With the completion of the National Family Health Sur-
vey III in 2006 and supplemental data from the National
Behavioral Surveillance Survey and the Integrated Biolog-
ical Behavioral Assessments Survey, India's National AIDS
Control Organization (NACO) reduced the official bur-
den of HIV infection to 2.5 million persons.[21] The epi-
demic is unevenly distributed across India, with six of
India's 28 states accounting for approximately two-thirds
of the estimated cases.[22] The 2006 estimates by NACO
indicate that prevalence is highest among men (61% of all
infections), the 15–49 age group (89%), and among high-
risk subgroups such as Injecting Drug Users (IDUs, 9% of
all infections), men who have sex with men (6%) and
female sex workers (5%). The 2006 estimates indicate that
the epidemic has stabilized in Tamil Nadu and other
southern states but increased in the northern and eastern
regions. Four of India's largest cities (Chennai, Delhi,
Mumbai and Chandigarh) have a significant population
living with HIV/AIDS, especially among IDUs. [23]
Of the estimated 785,000 people under 50 years of age,
living with HIV and in need of ART, only 24,000 were
reported by NACO to be receiving it in 2005. Access to
these allopathic drugs has been increasing, primarily
through the rapid expansion of ART delivery in govern-
ment clinics; as of July 2007, over 100,000 patients were
receiving ART in over 120 sites throughout India. [23]
While the government scale-up in public hospitals and
clinics now accounts for the majority of patients receiving
ART, antiretroviral drugs are also provided through the
private sector. [24] The complex medical health care seek-
ing behaviors in India render many patients still in needPage 3 of 9
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pay out-of-pocket and receive care in private clinics, and
lower-income patients often come to the public sector for
hospitalized care when their resources have been
expended. [25]
Little is known about TIMH use or its risk and benefits in
HIV/AIDS management.[26] A survey of 1,667 HIV-
infected persons in 4 regions of India found that 41%
reported using some form of TIMH although only 5%
believed TIMH was more effective than allopathic ART.
[27] With many products prepared locally as well as avail-
able on the market and claims of "cure" being made, [28]
there is a need for patients, providers and policy makers to
assess systematically the potential benefit as well as poten-
tial harm associated with TIMH therapies for HIV/AIDS.
Previous studies have shown that some natural medicines
such as botanicals and herbal products can be potentially
harmful to patients and thus, this is a research area of cru-
cial importance that requires further investigation.
Purpose
The purpose of this review was to survey and assess the
quantity and quality of published, English-language liter-
ature on TIMH for HIV/AIDS treatment and care. Meta-
analysis was neither intended nor possible due to the
diversity of TIMH practices, therapies, and outcome meas-
ures in the extant literature. Quality scoring, such as
assigning Jadad scores, [29] was not performed, since this
was intended to be a descriptive review.
Methods
To identify studies on HIV/AIDS and TIMH, MEDLINE,
EMbase, BIOSIS, CINAHL, clinical trials.gov, the
Cochrane Library and the National Library of Medicine
catalog were searched using the following keyword
sequence: [HIV and/or AIDS and India* and traditional
medicine or ayurved* or unani or siddha or naturopathy
or homeopathy or yoga]. Only studies in English were
reviewed. Bibliographies of review and other relevant arti-
cles were searched for relevant Indian literature, as well as
a bibliography of Indian medicine [30] and several easily-
accessible Indian journals. A list of these additional jour-
nals is available upon request. Several reports and confer-
ence proceedings were also searched for relevant
literature. Experts in each of the major systems of TIMH
were contacted to request that they review the draft bibli-
ography and identify additional key Indian literature in
their fields of expertise. A list of these experts contacted is
in the acknowledgments section.
Study selection
We examined studies focused on the impact of TIMH on
HIV/AIDS in vivo, in vitro and in clinical studies. Abstracts
from the initial electronic searches were searched to select
studies that met the following inclusion criteria: English-
language, peer-reviewed literature, published after the first
case reported of HIV in India in 1986 through October
2008. Randomized controlled trials, experimental studies,
observational studies, descriptive studies, and reviews of
HIV and TIMH were included, while ethnographic litera-
ture was excluded.
Two reviewers (MF and CC) independently screened the
titles and abstracts of all of the literature collected through
the searches. If both reviewers agreed that the abstract was
relevant, the full article was accessed and a second phase
of screening was conducted. All studies passing these
screening phases were included in the full descriptive
review.
Results
Of 206 original articles reviewed, 36 were relevant and
met the inclusion criteria described above. These 36 arti-
cles contained 38 relevant studies, 21 laboratory and 17
clinical. The majority of articles were excluded because
they were not based on actual research studies, were not
in English, or were surveys of TIMH usage. A bibliography
of all included studies can be found in Additional File 1:
Bibliography of Included Studies, and summaries of each
of these studies can be found in Additional File 2: Sum-
maries and Critiques of Included Studies.
Review articles
A total of 6 previous reviews of the literature were identi-
fied that covered at least one system of TIMH. The review
by Vermani and Garg [31] on TIMH for sexually transmit-
ted diseases and AIDS was not exclusive to Ayurveda or to
only HIV/AIDS, but it identifies many studies of Indian
Ayurvedic herbs for HIV care, all of which we have
included here. Ozsoy and Ernst [32] completed a system-
atic review on the effectiveness of complementary thera-
pies for HIV/AIDS, which included only randomized,
controlled studies on therapies such as herbal treatments,
vitamins and other supplements, stress management and
massage therapy. Mills et al. [33] reviewed complemen-
tary therapies for HIV treatment such as stress manage-
ment, natural health products, massage, acupuncture,
homeopathy and low-dose isopathy. Ullman [34] con-
ducted a review on homeopathy for HIV care and identi-
fied five controlled clinical trials, three of which met our
inclusion criteria. Martin and Ernst [35] completed a sys-
tematic review of antiviral agents derived from plants and
herbs, but only one of the studies focused on HIV. Finally,
Ernst's [36] systematic review of complementary AIDS
therapies focused mainly on vitamins, massage, acupunc-
ture and imagery, their prevalence of use, and treatment
safety and costs.Page 4 of 9
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laboratory studies and 17 clinical studies) that are rele-
vant to TIMH and HIV/AIDS. Most studied Ayurvedic
herbs and homeopathic preparations, and none of the
articles reviewed addressed naturopathy or Unani medi-
cine.
Laboratory studies
Since the goal of this review was to assess the quality of
published literature on TIMH for HIV/AIDS treatment and
care, our main focus was on clinical research. However, 21
laboratory studies met the inclusion criteria and are sum-
marized in Additional File 3: Table of Laboratory Studies.
[37-57] Most of these studies involved cell lines, and the
most commonly used was the H9 cell line. All reviewed
studies examined Indian Ayurvedic herbs, and there were
multiple studies on gossypol (Gossypium spp.), Phyllanthus
niruri, curcumin (Curcuma longa), and neem (Azadirachta
indica). Many studies used a controlled experimental
model, with uninfected or mock infected cells as the con-
trols. Almost all of these studies reported positive effects
on HIV infection rates; however, many of these studies
had significant methodological flaws, lacked information
about product standardization, and had insufficient out-
come measures and reporting.
Clinical studies
Seventeen of the clinical research studies reviewed met the
inclusion criteria. [6,57-70] A summary and critique of
each of these clinical studies appears in Additional File 2:
Summaries and Critiques of Included Studies, and Addi-
tional File 4: Table of Clinical Studies lists all studies
included according to each system of TIMH. Most studies
examined either Ayurvedic or homeopathic treatments for
persons with HIV/AIDS. One study of Siddha medicine
and one of yoga therapy were identified; no studies of
naturopathic treatments for HIV/AIDS in India were
found. Only four studies identified were randomized con-
trolled trials; the others were pilot studies, case reports,
observational and pre-post clinical studies. All of the stud-
ies were limited by small sample sizes (mean: 46 partici-
pants per study, range: 1–173 participants). Ten studies
were published in MEDLINE-indexed journals. Overall,
the studies reported positive effects, and some even sug-
gested "cure," defined as seroconversion to HIV-negative
status. Studies that reported effectiveness and improved
outcomes include those of Ayurvedic and homeopathic
treatments such as Boxwood (Boxus sempervirens), [67]
Andrographolide (Andrographis paniculata), [62] and
neem (Azadirachta indica), [57] as well as the Siddha com-
bination therapy RAN (Rasagandhi mezhuga, Amukkara
chooranum and Nellikkai lehyam).[6] The reader is referred
to Additional File 2: Summaries and Critiques of Included
Studies for a detailed summary and critique of each of
these studies.
Discussion
Overall, we found the methodological quality of pub-
lished research on TIMH for HIV/AIDS to be poor, regard-
less of study design. General reasons for this poor
methodological quality included lack of details on prod-
ucts and their standardization, small sample sizes, and
high loss-to-follow-up rates. Design flaws included selec-
tion of inappropriate and/or weak outcome measures,
uncertain representativeness of the study population,
inadequate methods for determining exposure and out-
come in observational studies, and short follow-up peri-
ods. Reporting flaws included incomplete reporting of
study results, inadequately described withdrawals and
dropouts, and reporting data only on those completing
therapy. The four RCTs identified did not adequately
report methods of randomization, blinding, withdrawals,
and concealment of treatment allocation, as recom-
mended by the Consolidated Standards of Reporting Tri-
als (CONSORT) statement [71] that is aimed at the
improvement of the quality of research reports of RCTs.
Analytical flaws included weak handling of missing data,
statistical analysis of data from non-completers using the
last observation carried forward, and inadequate exami-
nation of the roles of patient characteristics, non-specific
effects and other mediators, moderators and confounders
of reported positive effects.
In sum, these methodological challenges and flaws in
design, reporting and statistical analysis introduce bias
and call into question the reviewed studies' internal and
external validity. Claims of "cure" must be scrutinized
since clinical and symptomatic diagnosis of AIDS is com-
monplace throughout much of the developing world, and
establishment of an HIV-positive diagnosis through labo-
ratory testing and routine confirmatory procedures (e.g.,
ELISA or Western Blot) is often cost-prohibitive.
Limitations
This review may not represent all published literature on
TIMH and HIV/AIDS, since neither the non-MEDLINE lit-
erature in India nor any other non-English literature was
reviewed. Relevant unpublished articles and reports may
have been missed, since the grey literature was not system-
atically searched. However, we suggest that searching the
Indian literature would not have provided much added
value for the following three reasons. First, we searched
Indian Government reports on TIMH and HIV/AIDS and
did not glean any additional important literature. Second,
we spoke with several TIMH experts at a 2006 Research
Agenda Conference on TIMH and contacted additional
experts in each TIMH modality (see Acknowledgements
section below), and these experts did not identify much
additional important literature. Third, one author (IC)
conducted a systematic review of Ayurvedic interventions
for Diabetes Mellitus with colleagues at the RAND Corpo-Page 5 of 9
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and the authors of this RAND review conducted a focused
review of the Indian Ayurvedic literature and concluded
that "limiting the language to English would decrease the
literature yield, but we did not see evidence that it would
significantly decrease the availability of studies most
likely to be included in our review." [72]
Research gaps
The Indian government has acknowledged that published
data are sparse regarding the use, effectiveness and mech-
anism of action of TIMH in the treatment of HIV/AIDS.
[1] Therefore, a pragmatic research agenda and concomi-
tant funding are needed. As a first step in this process
toward engaging the TIMH community and toward devel-
oping a research agenda, the Samueli Institute, Johns
Hopkins University, the Indian Council of Medical
Research and Seth Gordhandas Sunderdas Medical Col-
lege/King Edward Memorial Hospital convened a research
agenda conference on TIMH for HIV/AIDS in New Delhi
in September 2006. Conference participants identified the
following as priority areas: research training, infrastruc-
ture and methodology, effectiveness research, observa-
tional research/epidemiology, and product safety.
Additional areas where further research is needed are the
impact of TIMH on quality of life, identification of TIMH
therapies that could be used to treat HIV/AIDS-related
complications, and identification of potentially immune-
modulating TIMH compounds. Important safety-related
challenges include interactions between ART and TIMH
therapies for the management of HIV/AIDS, the unregu-
lated Indian pharmaceutical industry, quality and purity
issues, inadequate monitoring and standardization proce-
dures, the presence of insecticides and heavy metals in
TIMH treatments [73], and the availability of combina-
tions of herbs over the counter that may interact with each
other adversely and that may not be mentioned in ancient
Ayurvedic texts. [74] Product-driven studies must charac-
terize and standardize these compounds and then
progress through in vitro and in vivo studies and phased
clinical research culminating in methodologically sound
pilot studies, and eventually larger-scale trials of TIMH.
Due to their methodological shortcomings, studies
included in this review that reported positive effects [such
as those of Boxwood (Boxus sempervirens), [67] Androgra-
pholide (Andrographis paniculata), [62] neem (Azadirachta
indica), [57] and the Siddha combination therapy RAN
(Rasagandhi mezhuga, Amukkara chooranum and Nellikkai
lehyam)] should be replicated to determine whether these
initial positive effects can be confirmed and whether
future research is justified. Future studies would benefit
from larger samples, stronger designs, and clearer descrip-
tions of populations, controls and intervention compo-
nents under study. Imperative for reliability and validity is
greater care in analysis and reporting of results.
Challenges and proposed strategies to overcome them
Significant roadblocks to achieving these research goals
exist. A broad spectrum of TIMH practices is currently in
use, but there is limited availability of scientific informa-
tion on which to build testable hypotheses. It is difficult
to fit non-Western clinical practices that are often individ-
ualized for each patient into the Western, reductionist sci-
entific model. Finally, there is a general lack of scientific
expertise or a research culture within the TIMH practice
community and a weak TIMH clinical perspective in the
scientific community. The majority of TIMH research has
been conducted outside the traditional setting in which
the therapy was created and is practiced, which seriously
limits the model validity and generalizability of research
findings. [75] To overcome these roadblocks, both stand-
ard and innovative methodologies will be required, such
as whole systems research, rapid ethnographic assess-
ments and outcomes studies evaluating the use of TIMH
as it is currently being practiced within India, and as an
adjunct to allopathic care.
As previously stated, TIMH providers outnumber allo-
pathic providers in India and serve as the primary method
for delivering primary care for a majority of India's popu-
lation. Across the socioeconomic spectrum, private medi-
cal facilities are the preferred source of care [76,77].
India's community-based and culturally relevant TIMH
system is the predominant method of treating symptoms
in rural and resource-poor settings and among patients
who may not trust the allopathic system or find it cultur-
ally dissonant. Amidst a culture of mutual lack of knowl-
edge, understanding, trust and recognition between the
allopathic and TIMH systems, the recent use of TIMH ther-
apies by allopathic providers and allopathic therapies
(e.g., antibiotics) by TIMH providers is a cause for concern
and action, since adverse drug-TIMH interactions have
been identified and providers have not received the edu-
cation necessary for safe administration of therapies out-
side of their area of training and expertise. [78]
While it would be imprudent to promote use of TIMH in
place of allopathic medicines for HIV/AIDS, we propose
that consideration be given by the Indian Medical Associ-
ation to recognizing TIMH providers and to training them
in providing coordinated care (in collaboration with their
allopathic counterparts) to the millions of HIV infected
patients for whom they already provide care. Further-
more, we propose that a sound, evidence-based model of
integrative HIV/AIDS care that is based on enhanced
cross-training and collaboration between TIMH and allo-
pathic practitioners and solid safety and effectivenessPage 6 of 9
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among HIV positive individuals in India.
In summary, this review exposes a broad gap between the
current widespread use of TIMH therapies for HIV/AIDS
in India, and the research base supporting their effective-
ness, efficacy and safety. The therapeutic effects of TIMH
for HIV/AIDS cannot be established based on the current
literature; most studies published to date in the English-
language literature lack sufficient clarity and rigor of
reporting to assess reliably and quantitatively the quality
of results. The lack of high-quality evidence highlights the
need for rigorous investigation of both whole systems of
TIMH, as well as individual therapies. In light of the sub-
optimal effectiveness of vaccines, ART, barrier methods
and behavior change strategies for prevention and cure of
HIV infection, it is both important and urgent to develop
a collaborative research agenda that uses rigorous meth-
odologies to investigate, evaluate and better understand
the role of TIMH in managing HIV/AIDS and associated
illnesses in India.
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